Scarica l'app Stockscreener
6.4072
3.55%
0.2072
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.20
Aprire:
$6.23
Volume 24 ore:
369.14K
Relative Volume:
0.24
Capitalizzazione di mercato:
$1.31B
Reddito:
-
Utile/perdita netta:
$-129.48M
Rapporto P/E:
-11.47
EPS:
-0.5584
Flusso di cassa netto:
$-106.97M
1 W Prestazione:
+4.22%
1M Prestazione:
+26.13%
6M Prestazione:
+11.27%
1 anno Prestazione:
+174.36%
Intervallo 1D:
$6.17
$6.415
Intervallo di 1 settimana:
$6.00
$6.415
Portata 52W:
$2.23
$7.005
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
6.395 | 1.27B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
520.10 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
669.53 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.65 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.22 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.25 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Ripresa | Oppenheimer | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
Price to sales forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline - The National Law Review
Securities Lawsuit Alert: Savara Inc. (SVRA) InvestorsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline - The National Law Review
SVRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Notifies Savara Inc. (SVRA) InvestorsLead Plaintiff Deadline on November 7, 2025 - The National Law Review
Investors SueWallSt as Savara Inc. Faces Securities Fraud Allegations - The National Law Review
Investors in Savara Inc. (SVRA): Protect Your RightsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Savara, Inc. Actuals & Estimates (FWB:YB4P) - TradingView
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI - Kavout | AI
Savara, Inc. Actuals & Estimates (SWB:YB4P) - TradingView
YB4P Forecast — Price Target — Prediction for 2027 - TradingView
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com - Investing.com Australia
Savara CFO David Lowrance sells $2.24m in company stock - Investing.com UK
Form 4 Savara Inc For: 22 June By Investing.com - Investing.com Nigeria
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
Form 144 Savara Inc For: 22 June By Investing.com - Investing.com South Africa
[144] Savara Inc SEC Filing - Stock Titan
Does Savara’s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)? - simplywall.st
Savara StockLong-term pipeline story in rare lung disease - AD HOC NEWS
Savara Grants Equity Awards to New Hires Amid Growth Push - MyChesCo
Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Shifts Finance Leadership Ahead of Key Drug Milestone - MyChesCo
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Savara Inc (SVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Savara (SVRA) Proxy filing Summary - Quartr
What Is Driving Attention Toward Savara’s Rare Disease Strategy? - Kalkine Media
Savara: Lowrance Will Remain Available in Advisory Capacity >SVRA - Moomoo
Savara Announces New Employment Inducement Grant - Business Wire
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role - simplywall.st
Savara shareholders approve share increases and executive changes at annual meeting - Investing.com Australia
Savara (SVRA) Announces Leadership Changes in Finance Department - GuruFocus
Savara shareholders approve share increases and executive changes at annual meeting By Investing.com - Investing.com South Africa
Savara Expands Share Capital and Updates Executive Leadership - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Savara CFO Dave Lowrance steps down; COO Robert Lutz takes on CFO role amid leadership reshuffle - Pluang
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Savara Inc Azioni (SVRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Jun 22 '26 |
Sale |
5.68 |
394,528 |
2,241,432 |
536,032 |
0.82%
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):